Alector, Inc.
ALEC • Healthcare
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
Quality Assessment
Alector, Inc. is a high-risk healthcare company with a Compass Score of 2. This stock has poor quality metrics and high risk. Not recommended for conservative investors.
Score Breakdown
The Compass Score is based on 6 quality factors identified by academic research.
Click any factor to see detailed metrics
Valuation Metrics
Click any metric for details
Technical Overview
Click any metric for details
Wall Street View
Growth Projections
Financial Health
Click any metric for details
Similar High-Quality Stocks
Important Disclaimer
The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.
Unlock Detailed Metrics
Upgrade to Basic to see the actual financial values behind each quality factor.
- See exact ROA, cash flow ratios, and more
- Unlimited stock lookups
- Export data to CSV
- 7-day free trial included
Cancel anytime